Medicina Cutánea Ibero-Latino-Americana

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Medicina Cutánea Ibero-Latino-Americana >Year 2009, Issue 5

Miyares CM, Hollands BI, Miyares DE, Pernas GA
Effectiveness of human placental extract with calcium (melagenina plus) for the treatment of vitiligo
Med Cutan Iber Lat Am 2009; 37 (5)

Language: Español
References: 23
Page: 207-212
PDF: 224.39 Kb.

Full text


Human placental alcohol extract have been successfully used on melanogenesis and melanocyte proliferation. Such extracts cause an increase in the number of melanocytes and melanin granules when applied topically on the ears and tails of black mice.
Objetives: Assessment of the effectiveness of a human placental alcohol extract with calcium (Melagenina Plus®) for the treatment of vitiligo, since this disease is characterized by melanocyte loss and consequently of melanine pigment.
A retrospective study was carried out with 300 cuban vitiligo patients which were chosen because of their correct application on their depigmented areas of the human placental alcohol extract with calcium. Patients selection was made among those involved in the treatment with Melagenina Plus from the Clinical Service of the Placental Histotherapy Center since 1998 to 2003.
At the end of the study, 231 patients showed total or marked repigmentation, 28 moderate repigmentation, 24 no repigmentation and 17 new lesions. Results demonstrate that placental alcohol extracts with calcium added can be very effective and innocuous for the vitiligo treatment.

Key words: treatment, vitiligo, placenta.


  1. Peral E, Grimes MD. New Insights and new therapies in Vitiligo. JAMA 2005; 293: 730- 5.

  2. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for Vitiligo. Cochrane Database Syst Rev 2006; 25: CD003263.

  3. Zhang XJ, Chen JJ, Liu JB. The genetic concept of Vitiligo. J Dermatol Sci 2005; 39: 137-46.

  4. Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of Vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003; 16: 322-32.

  5. Kemp E H, Waterman EA, Weltman A P. Autoimmune aspects of Vitiligo. Autoimmunity 2001; 34: 65-77.

  6. Njoo MD, Westerhoj. W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-81.

  7. Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64: 89-107.

  8. Roelandts R. Photo (Chemo) Therapy for Vitiligo. Photodermatol Photoimmunol Photomed 2003; 19: 1-4.

  9. Kreuter A, Gambichler T, Avermaete A, Jansen T, Altmeyer P, Von Kobyletzti G. Localized Vitiligo successfully treated with creampsoralen + ultraviolet A. J Eur Acad Dermatol Venereol 2001; 15: 357-8.

  10. De Leeuw J, Van der Beek N, Maierhofer G, Neugebauer WD. A case study to evaluate the treatment of Vitiligo with Khellin encapsulated in L-phenylalanin stabilized phosphatidylcholine liposomes in combination with ultraviolet light therapy. Eur J Dermatol 2003; 13: 474-7.

  11. Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmetation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol 2004; 50: 63-7.

  12. Cockayne SE, Messenger AG, Gawkrodger DJ. Vitiligo treated with topical corticosteroides: children with head and neck involvement respond well. J Am Acad Dermatol 2002; 46: 964-5.

  13. Njoo MD, Bossuyt PM, Westerhof W. Management of Vitiligo. Results of a questionnaire among dermatologists in the Netherlands. Int J Dermatol 1999; 38: 866-72.

  14. Parsad D, Saini R, Nagpal R. Calcipotriol in Vitiligo: a preliminary study. Pediatr Dermatol 1999; 16: 317-20.

  15. Miyares C, Táboas M. Estudio experimental y clínico del efecto pigmentante epidérmico del extracto placentario humano. Rev Cub Med 1981; 20: 7-12.

  16. Mal’tsev UI, Kaliuzhnaia LD, Gubko LM. Experience in introducing the method of placental therapy in Vitiligo in Ukraine. Lik Sprara 1995; 123-5.

  17. Xu AE, Wei Xo. Topical Melagenina for repigmentation in twenty-two child patients with Vitiligo on the scalp. Chin Med J (Engl) 2004; 117: 199-201.

  18. Miyares C. Melanogenic Human Placental Extract is shown to Repigment Vitiligo. Dermatology News 1991; 24: 1 y 7.

  19. Miyares C, González T. Simulationg the synthesis of Melanotic pigment in the skin. Br Uk Pat 1984; 2: 124, 900 (Chem Abs 1984; 100: 215533, 1984).

  20. Miyares C. Melagenina Plus. Avances Médicos de Cuba 2000; 7: 50-2.

  21. Sherbrookc WC, Hadley ME, De L. Castrucci AM. The Melanotropic Peptides. Vol: II. United State, CRC PRESS. Inc. Boca Raton, Florida, 33431, 1988; 182-4.

  22. Miyares C, Táboas M, López M. Informe preliminar sobre el empleo del extracto placentario humano en la terapéutica del Vitiligo. Rev Cub Farm 1976; 10: 67-72.

  23. Miyares C. Melagenina único recurso eficaz contra el Vitiligo. Madrid. España. Editorial Científico Técnica. 1998; 157-83.

>Journals >Medicina Cutánea Ibero-Latino-Americana >Year 2009, Issue 5

· Journal Index 
· Links 

Copyright 2019